Cell culture is of vital importance in the life sciences industry for both research and industrial use. On the research front, cell cultures find extensive application in toxicology studies for initial-stage screening of compounds in drug discovery. Cell/tissue culture involves a diverse assortment of media, sera and reagents. Products essential for sustenance of cells grown in a defined mixture are termed as cell culture media. Cell culture media are pH-balanced blends of amino acids, salts, vitamins, and sugars, which supply essential nutrients required for cell growth in an artificial environment. Cell culture media includes a wide range of products, such as nutrient media solutions, powdered nutrient media, antibiotics, balanced salt solutions, buffers and stock reagent concentrates. Major application areas of cell/tissue culture include biotechnology, microbiology, medicine, pharmaceuticals, agriculture, cosmetics and food additives. These and other market data and trends are presented in "Cell/Tissue Culture Supplies: A Global Market Perspective" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
Allegra Strategies is proud to release the 2012 report on European branded coffee shop market, providing comprehensive research on this fast developing market.The ProjectCaf
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
Allegra Strategies is proud to release the 2012 report on European branded coffee shop market, providing comprehensive research on this fast developing market.The ProjectCaf
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The biomass market suffered during the economic downturn in the face of low coal prices, logistic barriers and supply issues. 2010 saw more movement in the sector as coal prices are beginning to rise once again making co-firing coal plants with biomass more attractive. Furthermore, the biomass component of a coal-fired plant may be eligible for feed-in tariff or count towards renewable portfolio standards.Most of these plants rely on wood pellets, often transported at great distance, rather than wood chips or other less dense biomass sources. In the wood pellets market, supplies from the US and Canada are cheaper than their European counterparts and thus North America is a major suppli- ers for European biomass plants. CIS countries, Russia, Australia and South Africa have entered as significant suppliers, which if they could ramp up supply, could be serious competitors to the US and Canada. Or in the case of Russia, resolve supply delay issues, could be one of the biggest players in the market.
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
Pompe Disease Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Pompe Disease Global Clinical Trials Review, H1, 2013" provides data on the Pompe Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pompe Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pompe Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The biomass market suffered during the economic downturn in the face of low coal prices, logistic barriers and supply issues. 2010 saw more movement in the sector as coal prices are beginning to rise once again making co-firing coal plants with biomass more attractive. Furthermore, the biomass component of a coal-fired plant may be eligible for feed-in tariff or count towards renewable portfolio standards.Most of these plants rely on wood pellets, often transported at great distance, rather than wood chips or other less dense biomass sources. In the wood pellets market, supplies from the US and Canada are cheaper than their European counterparts and thus North America is a major suppli- ers for European biomass plants. CIS countries, Russia, Australia and South Africa have entered as significant suppliers, which if they could ramp up supply, could be serious competitors to the US and Canada. Or in the case of Russia, resolve supply delay issues, could be one of the biggest players in the market.
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
Pompe Disease Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Pompe Disease Global Clinical Trials Review, H1, 2013" provides data on the Pompe Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pompe Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pompe Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
Communications Mining Series - Zero to Hero - Session 1DianaGray10
This session provides introduction to UiPath Communication Mining, importance and platform overview. You will acquire a good understand of the phases in Communication Mining as we go over the platform with you. Topics covered:
• Communication Mining Overview
• Why is it important?
• How can it help today’s business and the benefits
• Phases in Communication Mining
• Demo on Platform overview
• Q/A
How to Get CNIC Information System with Paksim Ga.pptxdanishmna97
Pakdata Cf is a groundbreaking system designed to streamline and facilitate access to CNIC information. This innovative platform leverages advanced technology to provide users with efficient and secure access to their CNIC details.
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...Neo4j
Leonard Jayamohan, Partner & Generative AI Lead, Deloitte
This keynote will reveal how Deloitte leverages Neo4j’s graph power for groundbreaking digital twin solutions, achieving a staggering 100x performance boost. Discover the essential role knowledge graphs play in successful generative AI implementations. Plus, get an exclusive look at an innovative Neo4j + Generative AI solution Deloitte is developing in-house.
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
Maruthi Prithivirajan, Head of ASEAN & IN Solution Architecture, Neo4j
Get an inside look at the latest Neo4j innovations that enable relationship-driven intelligence at scale. Learn more about the newest cloud integrations and product enhancements that make Neo4j an essential choice for developers building apps with interconnected data and generative AI.
A tale of scale & speed: How the US Navy is enabling software delivery from l...sonjaschweigert1
Rapid and secure feature delivery is a goal across every application team and every branch of the DoD. The Navy’s DevSecOps platform, Party Barge, has achieved:
- Reduction in onboarding time from 5 weeks to 1 day
- Improved developer experience and productivity through actionable findings and reduction of false positives
- Maintenance of superior security standards and inherent policy enforcement with Authorization to Operate (ATO)
Development teams can ship efficiently and ensure applications are cyber ready for Navy Authorizing Officials (AOs). In this webinar, Sigma Defense and Anchore will give attendees a look behind the scenes and demo secure pipeline automation and security artifacts that speed up application ATO and time to production.
We will cover:
- How to remove silos in DevSecOps
- How to build efficient development pipeline roles and component templates
- How to deliver security artifacts that matter for ATO’s (SBOMs, vulnerability reports, and policy evidence)
- How to streamline operations with automated policy checks on container images
zkStudyClub - Reef: Fast Succinct Non-Interactive Zero-Knowledge Regex ProofsAlex Pruden
This paper presents Reef, a system for generating publicly verifiable succinct non-interactive zero-knowledge proofs that a committed document matches or does not match a regular expression. We describe applications such as proving the strength of passwords, the provenance of email despite redactions, the validity of oblivious DNS queries, and the existence of mutations in DNA. Reef supports the Perl Compatible Regular Expression syntax, including wildcards, alternation, ranges, capture groups, Kleene star, negations, and lookarounds. Reef introduces a new type of automata, Skipping Alternating Finite Automata (SAFA), that skips irrelevant parts of a document when producing proofs without undermining soundness, and instantiates SAFA with a lookup argument. Our experimental evaluation confirms that Reef can generate proofs for documents with 32M characters; the proofs are small and cheap to verify (under a second).
Paper: https://eprint.iacr.org/2023/1886
UiPath Test Automation using UiPath Test Suite series, part 6DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 6. In this session, we will cover Test Automation with generative AI and Open AI.
UiPath Test Automation with generative AI and Open AI webinar offers an in-depth exploration of leveraging cutting-edge technologies for test automation within the UiPath platform. Attendees will delve into the integration of generative AI, a test automation solution, with Open AI advanced natural language processing capabilities.
Throughout the session, participants will discover how this synergy empowers testers to automate repetitive tasks, enhance testing accuracy, and expedite the software testing life cycle. Topics covered include the seamless integration process, practical use cases, and the benefits of harnessing AI-driven automation for UiPath testing initiatives. By attending this webinar, testers, and automation professionals can gain valuable insights into harnessing the power of AI to optimize their test automation workflows within the UiPath ecosystem, ultimately driving efficiency and quality in software development processes.
What will you get from this session?
1. Insights into integrating generative AI.
2. Understanding how this integration enhances test automation within the UiPath platform
3. Practical demonstrations
4. Exploration of real-world use cases illustrating the benefits of AI-driven test automation for UiPath
Topics covered:
What is generative AI
Test Automation with generative AI and Open AI.
UiPath integration with generative AI
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Enchancing adoption of Open Source Libraries. A case study on Albumentations.AIVladimir Iglovikov, Ph.D.
Presented by Vladimir Iglovikov:
- https://www.linkedin.com/in/iglovikov/
- https://x.com/viglovikov
- https://www.instagram.com/ternaus/
This presentation delves into the journey of Albumentations.ai, a highly successful open-source library for data augmentation.
Created out of a necessity for superior performance in Kaggle competitions, Albumentations has grown to become a widely used tool among data scientists and machine learning practitioners.
This case study covers various aspects, including:
People: The contributors and community that have supported Albumentations.
Metrics: The success indicators such as downloads, daily active users, GitHub stars, and financial contributions.
Challenges: The hurdles in monetizing open-source projects and measuring user engagement.
Development Practices: Best practices for creating, maintaining, and scaling open-source libraries, including code hygiene, CI/CD, and fast iteration.
Community Building: Strategies for making adoption easy, iterating quickly, and fostering a vibrant, engaged community.
Marketing: Both online and offline marketing tactics, focusing on real, impactful interactions and collaborations.
Mental Health: Maintaining balance and not feeling pressured by user demands.
Key insights include the importance of automation, making the adoption process seamless, and leveraging offline interactions for marketing. The presentation also emphasizes the need for continuous small improvements and building a friendly, inclusive community that contributes to the project's growth.
Vladimir Iglovikov brings his extensive experience as a Kaggle Grandmaster, ex-Staff ML Engineer at Lyft, sharing valuable lessons and practical advice for anyone looking to enhance the adoption of their open-source projects.
Explore more about Albumentations and join the community at:
GitHub: https://github.com/albumentations-team/albumentations
Website: https://albumentations.ai/
LinkedIn: https://www.linkedin.com/company/100504475
Twitter: https://x.com/albumentations
Unlocking Productivity: Leveraging the Potential of Copilot in Microsoft 365, a presentation by Christoforos Vlachos, Senior Solutions Manager – Modern Workplace, Uni Systems
Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
Pushing the limits of ePRTC: 100ns holdover for 100 daysAdtran
At WSTS 2024, Alon Stern explored the topic of parametric holdover and explained how recent research findings can be implemented in real-world PNT networks to achieve 100 nanoseconds of accuracy for up to 100 days.
20 Comprehensive Checklist of Designing and Developing a WebsitePixlogix Infotech
Dive into the world of Website Designing and Developing with Pixlogix! Looking to create a stunning online presence? Look no further! Our comprehensive checklist covers everything you need to know to craft a website that stands out. From user-friendly design to seamless functionality, we've got you covered. Don't miss out on this invaluable resource! Check out our checklist now at Pixlogix and start your journey towards a captivating online presence today.
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdfMalak Abu Hammad
Discover how MongoDB Atlas and vector search technology can revolutionize your application's search capabilities. This comprehensive presentation covers:
* What is Vector Search?
* Importance and benefits of vector search
* Practical use cases across various industries
* Step-by-step implementation guide
* Live demos with code snippets
* Enhancing LLM capabilities with vector search
* Best practices and optimization strategies
Perfect for developers, AI enthusiasts, and tech leaders. Learn how to leverage MongoDB Atlas to deliver highly relevant, context-aware search results, transforming your data retrieval process. Stay ahead in tech innovation and maximize the potential of your applications.
#MongoDB #VectorSearch #AI #SemanticSearch #TechInnovation #DataScience #LLM #MachineLearning #SearchTechnology
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdf
Cell/Tissue Culture Supplies - A Global Market Perspective
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Cell/Tissue Culture Supplies - A Global Market Perspective
Published on November 2009
Report Summary
Cell culture is of vital importance in the life sciences industry for both research and industrial use. On the research front, cell cultures
find extensive application in toxicology studies for initial-stage screening of compounds in drug discovery. Cell/tissue culture involves
a diverse assortment of media, sera and reagents. Products essential for sustenance of cells grown in a defined mixture are termed
as cell culture media.
Cell culture media are pH-balanced blends of amino acids, salts, vitamins, and sugars, which supply essential nutrients required for
cell growth in an artificial environment. Cell culture media includes a wide range of products, such as nutrient media solutions,
powdered nutrient media, antibiotics, balanced salt solutions, buffers and stock reagent concentrates. Major application areas of
cell/tissue culture include biotechnology, microbiology, medicine, pharmaceuticals, agriculture, cosmetics and food additives.
These and other market data and trends are presented in "Cell/Tissue Culture Supplies: A Global Market Perspective" by BizAcumen,
Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
Table of Content
CELL/TISSUE CULTURE SUPPLIESBMR-1178
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. MARKET DYNAMICS 4
Outlook 4
Biopharmaceutical Drugs Fuel Cell Culture Market 4
Market Scenario 4
Industrial vs. Academic 4
Segmental Outlook 5
Market Structure 6
Leading Players 6
3. TRENDS AND ISSUES 7
Surging Demand for Cell Culture Products 7
Cell/Tissue Culture Supplies - A Global Market Perspective Page 1/10
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Stem Cells and Vaccines - Key Drivers 7
Growing Acceptance for Hi-Veg Culture Media 7
Fed-Batch Cultures - a Big Hit with Large-Scale Bioprocessors 8
Changing Trend Towards Serum-Free Media 8
Proteomics and Pharmacokinetics to Drive Market Growth 9
CHO, Hybridomas and Mabs Dominate Mammalian Cell Culture 9
Sluggish Fetal Bovine Serum Market 9
Cell Therapy Market Witnesses Increasing Consolidation Activity 10
Specialty Media Growing in Demand 10
Emerging Alternatives to Conventional Serum Supplemented Media 10
Growth of Defined Media 11
Regulations Prompt Change in Trends 11
Media Optimization 11
Cell-Line Engineering Vs. Cell Culture Media 12
Other Trends 12
Underlying Threat to Cell Culture Industry 12
Manufacture-on-Demand: Gaining Momentum 12
Move Towards Contract Manufacturing 13
Factors Impacting Growth 13
Business Models Driving the Need for Contract Manufacturing 13
Trends in Contract Manufacturing 13
Target Sectors for Contract Manufacturers 13
4. PRODUCT FACTS 14
1. Media 14
2. Sera 14
3. Reagents 14
5. END-USE ANALYSIS 15
End-Use Applications 15
Cell Therapy 15
Growing by Leaps and Bounds 15
Cell Therapy Applications 16
Key Factors Affecting the Cell Therapy Market 16
Future Trends 16
6. CORPORATE DEVELOPMENTS 17
Invitrogen Establishes Dedicated Business Unit for Cell Therapy 17
Invitrogen Signs Deal to Acquire CellzDirect 17
Invitrogen Renews Agreement with Luminex Corporation 17
Millipore Signs Agreement with Solabia to Distribute Animal-
Free Hydrolysates 17
Affymetrix Acquires USB Corporation 18
SAFC to Expand Production Capacity of Viral Product 18
Lonza Signs Partnership Agreement with Sanofi to Produce Cell
Culture Vaccine 18
Millipore Releases New Primary Human Epithelial Cell Cultures 18
Millipore Expands Stem Cell Tested Initiative 19
BD Biosciences Debuts BD FACSAria' II System to Sort Cells 19
Invitrogen Introduces Specific SFM for the Mesenchymal Stem Cells 20
Cell/Tissue Culture Supplies - A Global Market Perspective Page 2/10
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Invitrogen Unveils SequalPrep' System 20
Invitrogen Introduces Animal Source-Free Substrate 20
Invitrogen Introduces GIBCO® FoamAway' Reagent 20
SAFC to Increase Fermentation Capabilities of High-Potency API 21
Vitrolife Extends Agreement with Cellartis 21
Sigma-Aldrich Inks Distribution Agreement with CellPath 21
Lonza Acquires two Subsidiaries of Cambrex Bio-Businesses 22
Novartis to Invest in a New Cell Culture Plant in Singapore 22
Invitrogen Signs Agreement with Biocon 22
Lonza and Bio*One form Joint Venture for Mammalian Cell
Culture Plant 22
BD Biosciences Announces Treyburn Expansion Plans 23
BD Biosciences Collaborates with Roche to Advance Cell Signal
Transduction Study 23
Invitrogen and RXi Pharmaceuticals Enter into Collaboration 23
Millipore Forms a Strategic Alliance with Novozymes 23
Invitrogen Collaborates with Cytori for Research on Adipose
Stem Cell 24
Invitrogen Signs Deal with Wave Biotech to Offer Media-Filled
Disposable Bioreactors 24
Thermo Fisher Launches NUNC In Vitro PDL Coated PETG Roller
Bottles 24
Thermo Fisher Scientific Introduces HyClone AdvanceSTEM' Cell
Culture Product Line 25
Thermo Fisher Scientific Introduces New Medium to Culture PER.
C6 Cell Line 25
Genetix Expands CloneMedia Semi-Solid Media Products 25
Sigma-Aldrich Introduces GenomePlex Tissue WGA Kit 26
SAFC Biosciences Launches LONG®R3IGF-I in Liquid Form 26
Invitrogen and Novocell Introduce Media for hESC Growth 26
Invitrogen Releases New Culture System 26
Invitrogen Introduces New Line of Engineered Stem Cells 27
BD Biosciences Partners with StemCell Technologies 27
Millipore Launches MEL Cell Lines 27
Irvine Scientific Expands Industrial Cell Culture Product Line 28
BD Biosciences Introduces BD FACSDiva' 6.0 Software 28
Millipore Unveils Nylon Net Steriflip® Filter Unit 28
Lonza Expands Product-Portfolio with Serum Free Media 29
Millipore Introduces New Medium for Human Embryonic Stem Cell
Research 29
Invitrogen Launches CytoGenie' Cytometry Software Tool 29
7. MAJOR PLAYERS 30
Affymetrix, Inc. (USA) 30
AMRESCO, Inc. (USA) 30
Analytical Biological Services, Inc. (USA) 30
BD Biosciences (USA) 30
Cell Culture Technologies, LLC (Switzerland) 31
Cell Essentials, Inc. (USA) 31
Irvine Scientific (USA) 31
Cell/Tissue Culture Supplies - A Global Market Perspective Page 3/10
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Lonza Biologics Plc (UK) 31
Mediatech, Inc. (USA) 31
Millipore Corporation (USA) 32
Medi-Cult A/S (Denmark) 32
MP Biomedicals (USA) 32
PerBio Science AB (Sweden) 32
PromoCell GmbH (Germany) 32
Sera Laboratories International (UK) 32
Sigma-Aldrich Corporation (USA) 33
SAFC Biosciences (USA) 33
Vitrolife AB (Sweden) 33
Wisent, Inc. (Canada) 33
8. MARKET ANALYTICS 34
9. THE UNITED STATES 38
Market Overview 38
Trend Towards Serum-Free Media 38
Liquid and Powdered Media Account for Major Share 39
Fetal Bovine Serum-Uses on a Decline 40
Bovine Serum Industry: Highly Unpredictable 41
Suppliers Searching for New Areas 41
Sustained Rise of Serum-Free and Protein-Free Media 41
Rise in Cell Culture Equipment Demand Leads to Innovation 41
End-Use Analysis 41
Factors Influencing the Market for Tissue and Cell Culture Media 42
Imports & Exports 43
10. CANADA 44
Imports & Exports 45
11. JAPAN 46
12. EUROPE 47
a. France 50
b. Germany 51
c. The United Kingdom 52
d. Italy 53
e. Rest of Europe 54
13. ASIA-PACIFIC 55
Rise of Cell Culture in Asia 55
India 55
Cell Culture Market Constituents 55
China 55
Cell/Tissue Culture Supplies - A Global Market Perspective Page 4/10
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
14. LATIN AMERICA 57
EXHIBITS
Table 1: Market Shares of Leading Players in US Cell/Tissue
Culture Market - 2005
Table 2: Global Cell/Tissue Culture Supplies Market by Region
for the Period 2007-2015 (Sales in US$ Million)
Table 3: Percentage Breakdown of Global Cell/Tissue Culture
Supplies Market by Region for the Years 2008 & 2012
Table 4: Global Media Cell/Tissue Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 5: Percentage Breakdown of Global Media Cell/Tissue
Market by Region for the Years 2008 & 2012
Table 6: Global Sera Cell/Tissue Culture Market by Region for
the Period 2007-2015 (Sales in US$ Million)
Table 7: Percentage Breakdown of Global Sera Cell/Tissue
Culture Market by Region for the Years 2008 & 2012
Table 8: Global Reagent Cell/Tissue Culture Market by Region
for the Period 2007-2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Global Reagent Cell/Tissue
Culture Market by Region for the Years 2008 & 2012
Table 10: Market Shares of Cell Culture Segments by Industrial
End Use Application in the US - 2004
Table 11: Market Shares of Cell Culture Segments by Academic
End Use Application in the US - 2004
Table 12: Market Shares of Leading Players in the US Cell
Culture Media Market - 2006
Table 13: Market Shares of Leading Players in the US Cell
Culture Serum Market - 2006
Table 14: Market Shares of Leading Producers of Fetal Bovine
Serum in the US in the Recent Past - 2004
Table 15: Market Shares of Research Applications in the US
Cell and Tissue Culture Market - 2004
Cell/Tissue Culture Supplies - A Global Market Perspective Page 5/10
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table 16: Market Shares of End Use Applications in the US Cell
Culture Reagents Market - 2004
Table 17: Market Shares of Leading Players in US Cell/Tissue
Culture Market - 2005
Table 18: US Imports of Preparation Culture Media by Source
Country - 2007 (US$ Thousand)
Table 19: US Exports of Preparation Culture Media by
Destination Country - 2007 (US$ Million)
Table 20: Cell/Tissue Culture Supplies Market by Segment in
the US: 2007-2015 (Sales in US$ Million)
Table 21: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in the US for the Years 2008 &
2012
Table 22: Canadian Imports of Preparation Culture Media by
Source Country - 2007 (in US$ Thousand)
Table 23: Canadian Exports of Preparation Culture Media by
Destination Country - 2007 (in US$ Thousand)
Table 24: Cell/Tissue Culture Supplies Market by Segment in
Canada: 2007-2015 (Sales in US$ Million)
Table 25: Percentage Breakdown of Cell / Tissue Culture
Supplies Market by Segment in Canada for the Years 2008 &
2012
Table 26: Cell/Tissue Culture Supplies Market by Segment in
Japan: 2007-2015 (Sales in US$ Million)
Table 27: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in Japan for the Years 2008 & 2012
Table 28: Cell/Tissue Culture Supplies Market in Europe:
2007-2015 (Sales in US$ Million)
Table 29: Percentage Breakdown of Cell/Tissue Culture Supplies
Market in Europe for the Years 2008 & 2012
Table 30: Cell/Tissue Culture Supplies Market by Segment in
Europe: 2007-2015 (Sales in US$ Million)
Table 31: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in Europe for the Years 2008 & 2012
Cell/Tissue Culture Supplies - A Global Market Perspective Page 6/10
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table 32: Cell/Tissue Culture Supplies Market by Segment in
France: 2007-2015 (Sales in US$ Million)
Table 33: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in France for the Years 2008 & 2012
Table 34: Cell/Tissue Culture Supplies Market by Segment in
Germany: 2007-2015 (Sales in US$ Million)
Table 35: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in Germany for the Years 2008 &
2012
Table 36: UK Exports and Imports of Prepared Culture Media -
2006 (in Tons and £ Millions)
Table 37: Cell/Tissue Culture Supplies Market by Segment in
the UK: 2007-2015 (Sales in US$ Million)
Table 38: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in the UK for the Years 2008 & 2012
Table 39: Cell/Tissue Culture Supplies Market by Segment in
Italy: 2007-2015 (Sales in US$ Million)
Table 40: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in Italy for the Years 2008 & 2012
Table 41: Cell/Tissue Culture Supplies Market by Segment in
Rest of Europe: 2007-2015 (Sales in US$ Million)
Table 42: Percentage Breakdown of Cell/Tissue Culture Supplies
Market by Segment in Rest of Europe for the Years 2008 & 2012
Table 43: Cell/Tissue Culture Supplies Market by Segment in
Asia-Pacific: 2007-2015 (Sales in US$ Million)
Table 44: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in Asia-Pacific for the Years 2008 &
2012
Table 45: Cell/Tissue Culture Supplies Market by Segment in
Latin America: 2007-2015 (Sales in US$ Million)
Table 46: Percentage Breakdown of Cell/ Tissue Culture
Supplies Market by Segment in Latin America for the Years 2008 &
2012
Cell/Tissue Culture Supplies - A Global Market Perspective Page 7/10
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
COMPANIES PROFILED
Cell/Tissue Culture Supplies - A Global Market Perspective Page 8/10
9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Cell/Tissue Culture Supplies - A Global Market Perspective
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 2 995.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Cell/Tissue Culture Supplies - A Global Market Perspective Page 9/10
10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Cell/Tissue Culture Supplies - A Global Market Perspective Page 10/10